Relationship between secretory leukocyte protease inhibitor levels in bronchoalveolar lavage fluid and postoperative pulmonary complications in patients with esophageal cancer

We have demonstrated that bronchoalveolar lavage fluid from chronic obstructive pulmonary disease patients contains higher levels of interferon-γ compared with controls. Interferon-γ is a potent inducer of various cathepsins and matrix metalloproteases. Therefore, we postulated that interferon-γ could induce protease expression by macrophages in acute and chronic lung disease. Chronic obstructive pulmonary disease patients had greater levels of cathepsin S and matrix metalloprotease-12 in their bronchoalveolar lavage fluid. Macrophages incubated with chronic obstructive pulmonary disease bronchoalveolar lavage fluid exhibited increased expression of cathepsin S and matrix metalloprotease-12, which was inhibited by the addition of interferon-γ-neutralizing immunoglobulin. Human secretory leukocyte protease inhibitor is an 11.7-kDa cationic non-glycosylated antiprotease synthesized and secreted by cells at the site of inflammation. We have demonstrated that secretory leukocyte protease inhibitor can inhibit interferon-γ-induced cathepsin S production by macrophages. Pretreatment of macrophages with secretory leukocyte protease inhibitor inhibited interferon-γ-induced inhibitor κB β degradation and activation of nuclear factor κB. Secretory leukocyte protease inhibitor may prove to be therapeutically important as a potential inhibitor of protease expression in chronic obstructive pulmonary disease.

Download Full-text

Tumor Necrosis Factor-α Production After Esophageal Cancer Surgery: Differences in the Response to Lipopolysaccharide Stimulation Among Whole Blood, Pleural Effusion Cells, and Bronchoalveolar Lavage Fluid Cells

Surgery Today ◽

10.1007/s005950050349 ◽

1999 ◽

Vol 29 (1) ◽

pp. 10-15 ◽

Cited By ~ 1

Author(s):

Yusuke Kimura ◽

Yasunori Yaegashi ◽

Nobuhiro Sato

Keyword(s):

Esophageal Cancer ◽

Pleural Effusion ◽

Tumor Necrosis Factor ◽

Bronchoalveolar Lavage ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Α ◽

Bronchoalveolar Lavage Fluid ◽

Lavage Fluid ◽

Factor Α ◽

Necrosis Factor

Download Full-text

Tumor necrosis factor-α production after esophageal cancer surgery: Differences in the response to lipopolysaccharide stimulation among whole blood, pleural effusion cells, and bronchoalveolar lavage fluid cells

Surgery Today ◽

10.1007/bf02482963 ◽

1999 ◽

Vol 29 (1) ◽

pp. 10-15 ◽

Cited By ~ 11

Author(s):

Yusuke Kimura ◽

Yasunori Yaegashi ◽

Nobuhiro Sato

Keyword(s):

Esophageal Cancer ◽

Pleural Effusion ◽

Tumor Necrosis Factor ◽

Bronchoalveolar Lavage ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Α ◽

Bronchoalveolar Lavage Fluid ◽

Lavage Fluid ◽

Factor Α ◽

Necrosis Factor

Download Full-text

Study on polymorphonucleocytal elastase-.ALPHA.1-protease inhibitor complex in bronchoalveolar lavage fluid(BALF).

Japanese Journal of Medicine ◽

10.2169/internalmedicine1962.27.60 ◽

1988 ◽

Vol 27 (1) ◽

pp. 60-63 ◽

Cited By ~ 3

Author(s):

Akira YOSHIDA ◽

Kaoru KURAMITSU ◽

Hiroaki AOKI ◽

Makoto NAGATA ◽

Hidenori KIKUCHI

Keyword(s):

Protease Inhibitor ◽

Bronchoalveolar Lavage ◽

Bronchoalveolar Lavage Fluid ◽

Lavage Fluid ◽

Inhibitor Complex

Download Full-text

Cisplatin-Induced Eosinophilic Pneumonia

Case Reports in Pulmonology ◽

10.1155/2014/209732 ◽

2014 ◽

Vol 2014 ◽

pp. 1-3

Author(s):

Hideharu Ideguchi ◽

Keisuke Kojima ◽

Susumu Hirosako ◽

Hidenori Ichiyasu ◽

Kazuhiko Fujii ◽

...

Keyword(s):

Computed Tomography ◽

Esophageal Cancer ◽

Bronchoalveolar Lavage ◽

Bronchoalveolar Lavage Fluid ◽

Ground Glass Opacity ◽

Lavage Fluid ◽

Eosinophilic Pneumonia ◽

Lymphocyte Stimulation Test ◽

Drug Induced ◽

Chest Computed Tomography

A 67-year-old man suffering from esophageal cancer was admitted to our hospital complaining of dyspnea and hypoxemia. He had been treated with cisplatin, docetaxel, and fluorouracil combined with radiotherapy. Chest computed tomography revealed bilateral ground-glass opacity, and bronchoalveolar lavage fluid showed increased eosinophils. Two episodes of transient eosinophilia in peripheral blood were observed after serial administration of anticancer drugs before the admission, and drug-induced lymphocyte stimulation test to cisplatin was positive. Thus cisplatin-induced eosinophilic pneumonia was suspected, and corticosteroid was effectively administered. To our knowledge, this is the first reported case of cisplatin-induced eosinophilic pneumonia.

Download Full-text